VTVT Stock Eyes Fresh High on Upbeat Diabetes Drug Data

The two analysts in coverage think VTVT could triple

Digital Content Manager
Sep 18, 2019 at 10:31 AM
facebook twitter linkedin


The shares of pharmaceutical issue vTv Therapeutics Inc (NASDAQ:VTVT) are up 3.5% at $1.78 this morning, following promising results for the company's mid-stage study of its diabetes treatment, TTP399. VTVT said the new therapy was able to reduce daily mealtime bolus insulin doses by 23%. The equity is eyeing its highest close in three months, in response. 

What's more, VTVT is once again testing its footing atop its 200-day moving average -- a trendline it has only closed north of one time since March. But while the security has seen an impressive surge in September so far, tacking on almost 40% this month, it is still off roughly 34% for the year.

While analyst coverage of VTVT is relatively quiet, the two on board are extremely bullish. Both call the penny stock a "buy," and the consensus 12-month target price is all the way up at $6.50 -- over three times the security's current perch. 

VTVT's solid September gains could have some short sellers falling off the bullish bandwagon, too. Short interest has dropped 4.7% in the last reporting period. The 1.4 million shares sold short still represent a whopping 18.1% of the VTVT's available float and would take seven days to cover at its average pace of trading, which could put some wind at the equity's back, should more of these pessimistic positions begin to unwind. 

 

 

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners